Expertise in
29
conditions

Dr. David Rubin

Family Medicine
Office
1278 60th St, 
Brooklyn, NY 
Expertise in
29
conditions
Office
1278 60th St, 
Brooklyn, NY 

Overview

David Rubin is a primary care provider, practicing in Family Medicine in Brooklyn, New York. Dr. Rubin is highly rated in 29 conditions, according to our data. His top areas of expertise are Colitis, Viral Gastroenteritis, Ulcerative Colitis, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 552 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Family Medicine

Licenses

Family Medicine in NY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Office
1278 60th St, Brooklyn, NY 11219

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 4 Study Evaluating Real-World Use of CDPATH™, a Crohn's Disease Risk Prediction Tool
A Phase 4 Study Evaluating Real-World Use of CDPATH™, a Crohn's Disease Risk Prediction Tool
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2025
Intervention Type: Other
Study Phase: Phase 4
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Enrollment Status: Terminated
Publish Date: January 05, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients With Crohn's Disease
Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients With Crohn's Disease
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Other
Study Phase: Not Applicable
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis
A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis
Enrollment Status: Completed
Publish Date: June 09, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX® 9 mg Extended-release Tablets as Add-on Therapy in Patients With Active, Mild or Moderate Ulcerative Colitis Not Adequately Controlled on a Background Oral 5-ASA Regimen
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX® 9 mg Extended-release Tablets as Add-on Therapy in Patients With Active, Mild or Moderate Ulcerative Colitis Not Adequately Controlled on a Background Oral 5-ASA Regimen
Enrollment Status: Completed
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 3
Evaluating a Prediction Tool and Decision Aid for Patients With Crohn's Disease
Evaluating a Prediction Tool and Decision Aid for Patients With Crohn's Disease
Enrollment Status: Completed
Publish Date: February 07, 2019
Intervention Type: Behavioral
Study Phase: Not Applicable
View 9 Less Clinical Trials

552 Total Publications

Impacts of COVID-19 pandemic on early life gut microbiome.
Impacts of COVID-19 pandemic on early life gut microbiome.
Journal: Gut microbes
Published: December 18, 2025
Similar Doctors
Expertise in
44
conditions
Dr. Fufu He
Family Medicine
Expertise in
44
conditions
Dr. Fufu He
Family Medicine

Gentle Healing Touch Inc

1508 Avenue U, 
Brooklyn, NY 
 (3.5 miles away)
718-376-3383
Languages Spoken:
English
See accepted insurances

Fufu He is a primary care provider, practicing in Family Medicine in Brooklyn, New York. Dr. He is highly rated in 44 conditions, according to our data. His top areas of expertise are Parinaud Oculoglandular Syndrome, Common Cold, Sutton Disease 2, and Aphthous Stomatitis.

Expertise in
84
conditions
Dr. Aleksandr Orlovskiy
Family Medicine
Expertise in
84
conditions
Dr. Aleksandr Orlovskiy
Family Medicine

Office

2829 Ocean Pkwy Ste 2, 
Brooklyn, NY 
 (3.8 miles away)
718-616-0500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Aleksandr Orlovskiy is a primary care provider, practicing in Family Medicine in Brooklyn, New York. Dr. Orlovskiy is highly rated in 84 conditions, according to our data. His top areas of expertise are Necrosis, COVID-19, Childhood Iron Deficiency Anemia, Gastrostomy, and Ureteroscopy.

Expertise in
16
conditions
Dr. Genia Bekker
Family Medicine
Expertise in
16
conditions
Dr. Genia Bekker
Family Medicine

Prime Care On The Bay LLC

1711 Sheepshead Bay Rd, 
Brooklyn, NY 
 (3.9 miles away)
718-332-6525
Languages Spoken:
English
See accepted insurances

Genia Bekker is a Family Medicine provider in Brooklyn, New York. Dr. Bekker is highly rated in 16 conditions, according to our data. Her top areas of expertise are Pelvic Inflammatory Disease, Vulvovaginitis, Angiomyoma, Uterine Fibroids, and Intrauterine Device Insertion.

Frequently Asked Questions about Dr. David Rubin

How do I make an appointment with Dr. David Rubin?

You can book an appointment with Dr. David Rubin by calling their office at 718-741-7100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David Rubin a top-rated expert for Colitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David Rubin is classified as an Elite expert for Colitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David Rubin specialize in?

While Dr. David Rubin is a Family Medicine, they have specific expertise in Colitis, Viral Gastroenteritis, and Ulcerative Colitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Family Medicine.

Does Dr. David Rubin participate in research or clinical trials?

Yes. Dr. David Rubin has published 552 articles and abstracts on conditions like Colitis. You can view a list of Dr. David Rubin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David Rubin accept my insurance?

Dr. David Rubin accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 718-741-7100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rubin's expertise for a condition
ConditionClose
View All 19 Advanced Conditions
View All 153 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile